Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “Novartis”
Sponsor: Novartis Pharmaceuticals
Cardiovascular Disease and Lipoprotein(a)
United States, Argentina, Australia, Austria, Belgium +38 more
Sponsor: Thomas Hope
Prostate Cancer · Prostate Cancer (Diagnosis) · High-risk Prostate Cancer · Localized Prostate Carcinoma
United States
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
United States, Argentina, Australia, Canada, China +20 more
Sponsor: Novartis Pharmaceuticals
Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Extensive-stage Small Cell Lung Cancer
United States, Australia, Canada, China, Czechia +11 more
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCRecruiting
Sponsor: Novartis Pharmaceuticals
Prostate Cancer
United States, Australia, Brazil, China, Hong Kong +6 more
Sponsor: Novartis Pharmaceuticals
Breast Cancer · Non-small Cell Lung Cancer (NSCLC) · Gastric/Gastroesophageal Junction (GEJ) Cancer · Bladder Cancer
United States, Australia, Canada, Japan
- Pediatric Long-Term Follow-up and Rollover StudyActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Diffuse Astrocytoma · Anaplastic Astrocytoma · Astrocytoma · Oligodendroglioma, Childhood
United States, Argentina, Australia, Belgium, Brazil +14 more
Sponsor: Novartis Pharmaceuticals
Breast Neoplasms · Carcinoma, Non-Small-Cell Lung
Netherlands
- Evaluation of Mesopic Visual Acuity and Patient Satisfaction Following Ray-Tracing-Guided LASIKRecruiting
Sponsor: Vance Thompson Vision
Astigmatism · Myopia
United States
Sponsor: Novartis Pharmaceuticals
Myeloid Leukemia, Philadelphia Positive
United States, China, France, Germany, Greece +9 more
Sponsor: Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) · Non-small Cell Lung Cancer (NSCLC) · HR+/HER2- Ductal Breast Cancer (BC) · HR+/HER2- Lobular Breast Cancer (BC)
Denmark, Japan
Sponsor: Stanford University
Large-cell Lymphoma
- A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With SecukinumabNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasms
United States, Austria, Belgium, Canada, Czechia +9 more
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
United States, Argentina, Australia, Belgium, Brazil +14 more
Sponsor: Novartis Pharmaceuticals
Asthma
Poland, South Africa
Sponsor: Novartis Pharmaceuticals
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
United States, Argentina, Bulgaria, Canada, Czechia +19 more
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
United States, Argentina, Australia, Austria, Belgium +45 more
Sponsor: Novartis Pharmaceuticals
Breast Cancer
Russia
Sponsor: Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
United States
- A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy ParticipantsNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
Healthy Participants
- Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III MelanomaActive Not Recruiting
Sponsor: Melanoma Institute Australia
Melanoma
Australia
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Systemic Lupus Erythematosus
United States, Argentina, Australia, Chile, Colombia +10 more
- An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus ErythematosusActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Systemic Lupus Erythematosus · Lupus Nephritis
Australia, France, Germany, Spain, Switzerland
Sponsor: Novartis Pharmaceuticals
Progressive Metastatic Castrate Resistant Prostate Cancer
United States, Australia, Canada, China, Denmark +9 more